Acute urticaria: what to do when second-generation H1-antihistamine up-dosing has not achieved full symptom control

In acute urticaria, escalating the second-generation H1-antihistamine to four times the standard dose is a recognised first step. When that approach does not deliver complete resolution, a structured next-line intervention is needed.

Previous treatment & why escalation is indicated

The preceding line used up-dosing of a second-generation H1-antihistamine up to four-fold the standard dose — agents in this group include bilastine, cetirizine, desloratadine, ebastine, fexofenadine, levocetirizine, mizolastine, and rupatadine. The target was complete symptom control: consistent absence of wheals and pruritus (UAS = 0). Failure to reach that threshold is the trigger for advancing to this protocol.

Next-line treatment approach

This protocol introduces a short course of oral systemic corticosteroids, aimed at reducing disease duration and activity during an acute exacerbation. Full prescribing details — including duration, dosing, and patient-specific considerations — are in the complete protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/all.70210

For acute urticaria and acute exacerbations of CSU, a short course of oral corticosteroids, that is, treatment of a maximum of up to 10 days, may, however, be helpful to reduce disease duration/activity.

If systemic corticosteroids are used, doses between 20–50 mg/day of prednisone equivalent are needed (dose is appropriate for adults and not children).

View source ↗